Comparison between MRC Infracon IPO and Q-Line Biotec IPO.
MRC Infracon IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Q-Line Biotec IPO is a SME Bookbuilding proposed to list at NSE SME.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Cumulative Capital Pvt.Ltd. | Share India Capital Services Pvt.Ltd. Hem Securities Ltd. |
| Registrar | Kfin Technologies Ltd. | Purva Sharegistry (India) Pvt.Ltd. |
| Market Maker | Hem Finlease Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of MRC Infracon IPO is up to ₹0.00 Cr whereas the issue size of the Q-Line Biotec IPO is up to ₹203.74 Cr. The final issue price of MRC Infracon IPO is and of Q-Line Biotec IPO is ₹343.00 per share.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹326.00 per share | |
| Issue Price (Upper) | ₹343.00 per share | |
| Issue Price (Final) | ₹343.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 400 shares | |
| Fresh Issue Size | 45,00,000 shares | 59,40,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹203.74 Cr |
| OFS Issue Size | 10,00,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 55,00,000 shares | 59,40,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹203.74 Cr |
MRC Infracon IPO opens on , while Q-Line Biotec IPO opens on May 21, 2026. The closing date of MRC Infracon IPO and Q-Line Biotec IPO is , and May 25, 2026, respectively.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Anchor Bid Date | May 20, 2026 | |
| Issue Open | May 21, 2026 | |
| Issue Close | May 25, 2026 | |
| Basis Of Allotment (Tentative) | May 26, 2026 | |
| Initiation of Refunds (Tentative) | May 27, 2026 | |
| Credit of Share (Tentative) | May 27, 2026 | |
| Listing date (Tentative) | May 29, 2026 | |
| Anchor Lockin End date 1 | Jun 25, 2026 | |
| Anchor Lockin End date 2 | Aug 24, 2026 |
MRC Infracon IPO P/E ratio is , as compared to Q-Line Biotec IPO P/E ratio of 20.82.
| MRC Infracon IPO | Q-Line Biotec IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 96.77 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 20.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹800.16 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 102.11 | 23.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.22 | 17.66 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.19 | 0.87 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹16.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 102.11 | 23.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the MRC Infracon IPO Retail Individual Investors (RII) are offered 0 shares while in Q-Line Biotec IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in MRC Infracon IPO and 11,88,000 shares in Q-Line Biotec IPO.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 17,81,200 shares |
| Market Maker Reservation | 0 shares | 3,13,200 shares |
| QIB | 0 shares | 11,88,000 shares |
| NII | 0 shares | 8,91,600 shares |
| RII | 0 shares | 20,79,200 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 59,40,000 shares |
MRC Infracon IPO subscribed in total, whereas Q-Line Biotec IPO subscribed 71.71x.
| MRC Infracon IPO | Q-Line Biotec IPO | |
|---|---|---|
| QIB (times) | 123.94x | |
| NII (times) | 145.98x | |
| Big NII (times) | 178.29x | |
| Small NII (times) | 81.35x | |
| RII (times) | 71.44x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 71.71x |
